<DOC>
	<DOCNO>NCT02839746</DOCNO>
	<brief_summary>Describe patient physician assess factor patient well-being treat Pradaxa stroke embolism prevention atrial fibrillation either compare previous antithrombotic treatment ( switcher )</brief_summary>
	<brief_title>Treatment Convenience Patients Treated With Dabigatran Stroke Prophylaxis Atrial Fibrillation ( SPAF )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : Written inform consent prior participation Female male patient 18 year age old diagnosis nonvalvular atrial fibrillation . At least 6 month continuous vitamin K antagonist ( VKA ) treatment stroke prevention prior baseline assessment . Patients switch Pradaxa® accord Summary Product Characteristics , therapeutic position report Spanish competent authority visa autonomous community . Exclusion criterion : Contraindication use Pradaxa® VKA describe Summary Product Characteristics ( SmPC ) Patients receive Pradaxa® VKA condition stroke prevention nonvalvular atrial fibrillation . Current participation clinical trial drug device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>